| MESSAGE FROM THE DIRECTOR |
Stan Gerson, MD
Director, Case Comprehensive Cancer Center
|
Case CCC Leadership Updates
 Mitchell Machtay, MD,
was appointed as Associate Director for Clinical Research, replacing Neal Meropol, MD who left our Center earlier this year. As Associate Director, Machtay oversees translation of basic laboratory findings to clinical application and conduct of clinical investigation. Machtay is Chairman of Radiation Oncology at UH Cleveland Medical Center and Professor at CWRU School of Medicine (SOM).
 Jaroslaw Maciejewski, MD, PhD,
former Associate Director for the Lerner Research Institute, was recently named Associate Director for Translational Research. In his new role, Maciejewski provides leadership in coordinating the transition of basic science discovery to disease models, sample cohorts, and genomics. Maciejewski is also Co-Leader of the Case CCC Hematopoietic and Immune Cancer Biology Program, and Chairman of the Translational Hematology and Oncology Research Department at Cleveland Clinic.
 Martina Veigl, PhD, Associate Professor of Oncology at CWRU SOM, was appointed as Associate Director for Shared Resources (SR). As a long-time SR Director and current Director of the newly reorganized Integrated Genomics SR, Veigl brings leadership and team science experience to oversee the 13 Case CCC Shared Resources.
 Junran Zhang, MD, PhD, Assistant Professor of Radiation Oncology at CWRU SOM, was named Director of the Radiation Resources Shared Resource (SR). Zhang most recently was a member of the Radiation SR Scientific Advisory Board, and was appointed SR co-Director prior to the departure of former SR Director Scott Welford.
|
UH Appoints Seidman Cancer Center President and Scientific Officer
 |
|
|
Theodoros Teknos
|
University Hospitals (UH) announced the appointment of
Theodoros N. Teknos, MD as the new President and Scientific Officer of Seidman Cancer Center. Teknos starts his new position October 1, replacing Nathan Levitan, MD, who announced his retirement earlier this year.
Daniel Simon, MD, President of UH Cleveland Medical Center, said Dr. Teknos is a "highly respected physician, researcher and administrative leader."
Dr. Teknos comes to UH from The Ohio State University Wexner Medical Center, where he has served in several leadership roles since 2008. He is currently Professor and Chair, Department of Otolaryngology - Head and Neck Surgery. Prior to Ohio State, he was Division Chief, Head and Neck Oncology Division, Department of Otolaryngology, at the University of Michigan Health System in Ann Arbor. From 2007 to 2014, Dr. Teknos co-chaired a Task Force on Recurrent and Metastatic Disease for the National Cancer Institute's Head and Neck Cancer Steering Committee.
At UH Seidman, Dr. Teknos will lead the development of strategic, business and marketing plans for UH Seidman, including cancer-related palliative care, integrative care and interface with UH Hospice care. He will oversee all inpatient and ambulatory cancer care delivered at facilities across the UH system. Dr. Teknos also will provide leadership of UH Seidman's academic components and the Clinical Trials Unit. As Deputy Director, he will direct UH Seidman's involvement in the Case Comprehensive Cancer Center.
View full announcement>
|
Upcoming Cancer Moonshot Funding Opportunities
The
next phase of the NCI Cancer Moonshot includes a number of very specific initiatives, most with short submission timelines.
Please add to your efforts a plan to review and respond.
These are high visibility and are worthy of your efforts.
The funding opportunities are expected to be formally released in the coming months, and awards are expected to be made pending the appropriation of fiscal year 2018 funding for Cancer Moonshot.
|
Huang wins St. Baldrick's Foundation Innovation Award
|
|
|
Alex Huang
|
Alex Huang, MD, PhD, co-Leader of the Hematopoietic and Immune Cancer Biology Program, received the Innovation Award from the St. Baldrick's Foundation. This $150,000 award will support work to increase the effectiveness of immnunotherapy efforts, with a special focus on brain tumors and solid tumors.
"This exciting innovation award from St. Baldrick's Foundation will provide funding to test novel hypothesis that will lead to the application of immune-based therapeutics for difficult-to-treat pediatric and adolescent cancers such as metastatic sarcomas and brain tumors," said Huang, Professor of Pediatrics at CWRU SOM and Associate Director of the Pediatric Hematology-Oncology Fellowship Program at UH Rainbow Babies and Children's Hospital. "Our goal is to offer these strategies to families here in Northeast Ohio and nationally in as short of a timeframe as possible."
Huang is a long-time supporter of St. Baldrick's, shaving his head yearly as part of their "Shave It Off" fundraising events. He has received two other grants from the Foundation. In 2008 he was recognized as a St. Baldrick's Scholar; the two-year award was extended an additional two years in 2011. He also received an Infrastructure Grant in 2015.
|
Biomedical Engineering Researchers Recognized by State of Ohio
|
|
|
Anant Madabhushi
|
|
|
|
Pallavi Tiwari |
A team of biomedical engineering researchers earned official commendations from the State of Ohio for its first-place finish in the collegiate division at the inaugural Medical Capital Innovation Competition earlier this year. The team, led by Pallavi Tiwari, PhD, Case Comprehensive Cancer Center, Assistant Professor of Biomedical Engineering, also included recent biomedical engineering graduate Prateek Prasanna, PhD and Anant Madabhushi, PhD, Case Comprehensive Cancer Center, F. Alex Nason II Professor of Biomedical Engineering.
The team won for its NeuroRadVision technology, which is described as "a computerized decision support software toolkit, employing novel and advanced artificial intelligence and image analysis algorithms to differential recurrent brain tumors from benign radiation-induced treatment effects."
|
2nd Annual Melanoma Conference
Aug 16 | InterContinental Hotel
Registration is open for the 2nd Annual Melanoma Conference:
Case-Based Discussion of Treatment Options for Melanoma,
Wednesday, August 16 from 10a-4p at the InterContinental Hotel and Conference Center.
This medical education program for health care professionals will feature guest panelist, Charles Balch, MD, PhD, Professor of Surgery, University of Texas MD Anderson Cancer Center. Dr. Balch serves on the editorial board of The Patient Resource Cancer Guide (founding Editor) and American Board of Surgery. He is President of The Society of Surgical Oncology and The American Joint Committee on Cancer of Melanoma Staging Committee Chairman.
To register, please contact Becky Habecker, Cleveland Clinic Taussig Cancer Institute Melanoma Program Manager, at
habeckb@ccf.org or 216.445.2612.
|
RNA Therapeutics Symposium
Aug 18 | Normandy Catering, Wickliffe
Conference organizers Ahmed Khalil and Jeff Coller invite you attend the RNA Therapeutics Symposium. This symposium will feature talks by Nicole Steinmetz, Mark Cameron, Drew Adams, Kristian Baker, Anton Komar, Rick Padgett, Analisa Difeo, Mitch Drumm and
Donny Licatalosi. Please RSVP to
jmc71@case.edu
by August 4th - space is limited.
|
NCRM Cell Therapy Retreat
Sep 8 | BRB 105
 The National Center for Regenerative Medicine will host a
Cell Therapy Retreat Friday, Sep 8 from 1-4:30p in BRB 105. This forum will promote scientific exchange and networking opportunities among cell therapy experts within the Cleveland area. Clinicians, researchers, trainees and students are welcome to attend. This is a free event. Pre-registration is required.
|
|
Call for Abstracts: 2nd Annual MetroHealth Cancer Center Symposium
Sep 22, 2017 | MetroHealth Medical Center
 We invite you to submit an abstract for MetroHealth's 2nd annual Cancer Center Symposium.
The theme for the symposium is "The Science of Preemptive Strike: Prevention and Early Detection of Cancers." All cancer-related topics such as medical oncology, palliative care, survivorship, navigation, as well as work in progress, will be considered for inclusion in the symposium. All accepted submissions will be considered for the Poster Session. Nurses and other allied health care providers, residents, fellows and medical students are invited to submit their original work. Previously presented work may also be submitted.
Abstract submission specifications:
- Abstracts must be sent directly to Jennifer Prechtel at jprechtel@metrohealth.org (216.778.2822) no later than August 25, 2017.
- Abstracts must be submitted as word documents.
- Abstracts are limited to 400 words.
- Posters should be no larger than 6 feet by 4 feet.
- Include the following:
- Title
- Institution
- Author(s)
- Category (i.e. oncology, palliative care, survivorship, navigation)
- Background
- Methods
- Results
- Conclusion
- You will receive an email confirmation within two business days following submission.
- Letters of acceptance will be emailed by August 29, 2017, to the first author/presenter.
|
Global Adolescent & Young Adult Cancer Congress
Dec 5-7, 2017 | Atlanta, GA
 Building on the success of Teenage Cancer Trust's International Conference Series and the professional global networks that have developed through subsequent world-wide advances in AYA cancer services, Teen Cancer America is proud to host the
2nd Global AYA Cancer Congress. This will be the first Congress held outside of the UK, in the wonderful host city of Atlanta, Georgia.
Healthcare professionals from across the world, including oncologists, hematologists, research scientists, psychologists, nurses, social workers, youth workers, allied health professionals, advocates, and more, are invited to join this groundbreaking summit.
Call for Abstracts
The Adolescent and Young Adult Cancer Global Accord invites submissions for presentation at the 2nd Global AYA Cancer Congress. Deadline to submit is Sep 1, 2017.
|
Right now, doctors here in Cleveland are inching closer to finding a permanent cure for childhood cancer.
They are looking at ways to use a patient's own immune system to fight the disease. As it turns out, a bunch of bald heads are helping to fund the potentially life-saving research...
"I personally have shaved my head for nine years now to raise money," said Dr. Alex Huang.
Huang just received a $150,000 award from the St. Baldrick's Foundation to continue his effort to find a cure for childhood cancer.
|
Medpage Today - Jul 21, 2017
A
recent report
indicated that oncology is dominating the drug R&D industry, with one-third of all drug studies from preclinical through phase III now involving anti-cancer agents...MedPage Today reached out to several industry thought leaders for their thoughts on the development of new therapies -- oncology-related and otherwise...Mikkael Sekeres, MD, MS, Cleveland Clinic: Cancer therapeutics is the perfect storm, as our understanding of cancer genesis has exploded, particularly over the past decade. Cancer is far from universally cured (thus representing an ever-present clinical need), while cancer drug pricing has become unsustainably high. A particular driver of this phenomenon is the parsing of even a single organ-based cancer into many molecular subtypes, each demanding its own targeted intervention.
|
Health Data Management - Jul 30, 2017
Radiology professionals are increasingly seeing new IT capabilities applied to image assessment. Early tests have suggested that these approaches are at least as accurate as clinicians. For example, a research team led by Case Western Reserve University studied whether a deep-learning network approach could identify invasive forms of breast cancer. The network was "trained" by downloading 400 biopsy images from multiple hospitals; then, the network was asked to analyze 200 images from The Cancer Genome Atlas and University Hospitals Cleveland Medical Center. According to Anant
Madabhushi
, professor of biomedical engineering at Case Western Reserve and co-author of the study, the network scored 100 percent accuracy in determining the presence or absence of cancer on whole slides.
|
|
CWRU Technology Validation & Start-Up Fund Program (CTP)
Preproposal: Aug 23, 2017; Full Proposal: Sep 9
The Technology Validation and Start-up Fund (TVSF), funded by the Ohio Third Frontier, aims to accelerate and fund the translation of promising technologies into the marketplace through Ohio start-up companies with the eventual goal of creating greater economic growth.
In October 2016, CWRU was awarded a $500,000 fund, which will be administered by the Technology Transfer Office as the CWRU TVSF Program ("CTP") to advance a number of selected programs over a 12-month period. As a result of this award CWRU investigators are no longer eligible to apply for TVSF funding directly to the State of Ohio, but must instead apply to this internal competition.
The CTP is intended to be the final bridge between a translational research project and a viable commercial program.
Funding will support technologies that require validation/proof that will directly impact and enhance commercial viability and the ability to support a start-up company. Projects must have already advanced beyond basic research and should have the equivalent of a laboratory-scale proof of concept prior to applying for funding.
All proposals must fall into one of these State of Ohio's technology focus areas:
- Biomedical/Life Sciences
- Advanced Materials
- Energy
- Software/Information Technology
- Sensors
- Advanced Manufacturing
|
Sartorius & Science Prize for Regenerative Medicine & Cell Therapy
Deadline: Oct 1, 2017
The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy is geared towards researchers focused on basic or translational research that advances regenerative medicine and cell therapy. Established in 2017, it is awarded for outstanding research performed by the applicant and as a mutual endeavor to raise awareness for the field. Every individual scientist who received his or her MD/PhD within the past 10 years may apply.
|
Request for Proposals for Case CCC Funding for Early Phase Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase (Phase 0, 1, pilot/feasibility) clinical trials of relatively short duration which are focusing on initial early phase testing of a candidate agent or device for the diagnosis, prevention detection or treatment of cancer.
This is the last year when EPCRS funds are available in their current form, as such this is the last chance to apply for funding for applicable studies. Proposals are being accepted on a rolling basis.
Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office,
katarzyna.karelus@case.edu, 216.844.4176.
|
NIH BULLETIN- Notices and Funding Opportunities
|
Notices
NIH Offers Assistance to Phase II HHS SBIR and STTR Awardees through the NIH Commercialization Accelerator Program (CAP) 2017-2018 (NOT-OD-17-097)
Notice of Correction in Expiration Date for PAR-17-331 "Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)"(NOT-CA-17-075)
Notice of Correction in Expiration Date for PA-17-330 "Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)"(NOT-CA-17-076)
Notice of Correction in Expiration Date for PAR-17-438, "Assay development and screening for discovery of chemical probes or therapeutic agents (R01)"(NOT-CA-17-077)
Call for Applications/Program Announcements
RFAs
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01)(RFA-CA-17-029)
Deadline: Oct 24, 2017; Jan 23, 2018
Cardiovascular and Pulmonary Research on E-Cigarettes (R01)(RFA-HL-18-024)
Deadline: Jan 16, 2018
Program Announcements
Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)(PA-17-444)
Deadline: Standard dates apply
Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)(PA-17-446)
Deadline: Standard dates apply
Administrative supplements for validation studies of analytical methods for dietary supplements and natural products (Admin. Suppl.)(PA-17-447)
Deadline: Oct 15, 2017; Jan 15, 2018; Apr 15, 2018
|
|
|
FOLLOW US
|
Have news or updates to share? Contact Gillian Irwin at
gmi@case.edu
|
EVENTS
|
|
Tues, Aug 8
Radiation Oncology Grand Rounds
William Grubb, MD
PGY-3, Physician Resident, Radiation Oncology, UHCMC
"Update in Non-small Cell Lung Cancer"
8:10a Lerner B-151
THOR Seminar
Janssen Oncology Pipeline
1p R3-027 |
|
Thurs, Aug 10
Developmental Therapeutics Journal Club
9a R4-013 |
|
Fri, Aug 11
TCI Grand Rounds
8a CA5-120 |
|
Mon, Aug 14
Mesenchymal Stem Cell Conference (MSC) 2017
Marriott Downtown at Key Center
Details |
|
Tues, Aug 15
Mesenchymal Stem Cell Conference (MSC) 2017
Marriott Downtown at Key Center
Details
THOR Seminar
Yang Dennis Du, PhD
Assistant Professor, Pediatrics, Uniformed Services University
1p R3-027 |
|
Wed, Aug 16
Mesenchymal Stem Cell Conference (MSC) 2017
Marriott Downtown at Key Center
Details
Melanoma Conference
InterContinental Hotel
|
|
Thurs, Aug 17
RNA Therapeutics Symposium
9a Normandy Catering Wickliffe
Email jmc71@case.edu to
register
Developmental Therapeutics Journal Club
9a R4-013 |
|
Fri, Aug 18
TCI Grand Rounds
8a CA5-120 |
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
Genomic Medicine Institute 5th Annual Genetics Education Symposium - Genetics and Genomics: A Focus on Women's Health
Sep 7, 2017
InterContinental Hotel
International Cancer Education Conference
Sep 13-15, 2017
Westin Cleveland Downtown
Responsible Opioid Management: Impact on Hospice and Palliative Care
Sep 22, 2017
Embassy Suites, Independence
MetroHealth Cancer Symposium
Sep 22, 2017
MetroHealth Medical Center
Deadline to submit abstracts: Aug 25, 2017
GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
Cleveland Clinic 2017 Medical Innovation Summit
Oct 23-25, 2017
Huntington Convention Center
Breast Cancer Update: From Screening Through Treatment to Survivorship
Nov 8, 2017
Embassy Suites, Independence
Global Adolescent & Young Adult Cancer Congress
Dec 5-7, 2017
Atlanta, GA
Deadline to submit abstracts: Sep 1, 2017
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Deadline: Open
Deadline: Open
Deadline: Open
|
|
 |
|
